{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:35:14Z","timestamp":1793907314867,"version":"4.8.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2022SF-13"],"award-info":[{"award-number":["2022SF-13"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.intimp.2022.109636","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T17:28:41Z","timestamp":1672248521000},"page":"109636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pneumocystis jiroveci Pneumonia secondary to tyrosine kinase inhibitor with blinatumomab therapy: A case report"],"prefix":"10.1016","volume":"115","author":[{"given":"Xiaoning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2022.109636_b0005","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1080\/14656566.2021.1915989","article-title":"Pneumocystis jirovecii: a review with a focus on prevention and treatment","volume":"22","author":"Benson Weyant","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"issue":"17","key":"10.1016\/j.intimp.2022.109636_b0010","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"GIMEMA Investigators. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109636_b0015","doi-asserted-by":"crossref","unstructured":"M. Reinwald, J. T. Silva, N.J. Mueller, J. Fort\u00fan, C. Garzoni, J. W de Fijter, M. Fern\u00e1ndez-Ruiz, P. Grossi, J.M. Aguado, ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin. Microbiol. Infect. 24 Suppl 2 (2018 Jun) S53-S70.","DOI":"10.1016\/j.cmi.2018.02.009"},{"key":"10.1016\/j.intimp.2022.109636_b0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","article-title":"Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin\u2019s lymphoma: a systemic review and meta-analysis","volume":"24","author":"Yu","year":"2019","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109636_b0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-0039-3399559","article-title":"Pneumocystis jiroveci","volume":"41","author":"Fishman","year":"2020","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.intimp.2022.109636_b0030","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"Cordonnier C.ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J. Antimicrob Chemother."},{"issue":"4","key":"10.1016\/j.intimp.2022.109636_b0035","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1097\/MJT.0000000000000963","article-title":"Imatinib-Associated Pneumocystis jirovecii Pneumonia in a Patient With Chronic Myeloid Leukemia","volume":"27","author":"Daw","year":"2020","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.intimp.2022.109636_b0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijid.2014.04.030","article-title":"Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment","volume":"25","author":"Chang","year":"2014","journal-title":"Int. J. Infect Dis."},{"key":"10.1016\/j.intimp.2022.109636_b0045","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.intimp.2022.109636_b0050","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/cid\/ciy1072","article-title":"Clinical Performance of (1,3) Beta-D Glucan for the Diagnosis of Pneumocystis Pneumonia (PCP) in Cancer Patients Tested With PCP Polymerase Chain Reaction","volume":"69","author":"Morjaria","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2022.109636_b0055","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/jof8080863","article-title":"Targeted NGS-Based Analysis of Pneumocystis jirovecii Reveals Novel Genotypes","volume":"8","author":"Pungan","year":"2022","journal-title":"J. Fungi (Basel)"},{"issue":"26","key":"10.1016\/j.intimp.2022.109636_b0060","first-page":"e931059","article-title":"Application of MetagenomicNext-Generation Sequencing to Diagnose Pneumocystis jirovecii Pneumonia in Kidney Transplantation Recipients","volume":"8","author":"Xu","year":"2021","journal-title":"Ann. Transplant."},{"issue":"9","key":"10.1016\/j.intimp.2022.109636_b0065","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10096-021-04254-x","article-title":"Application of metagenomic next-generation sequencing in the diagnosis and treatment guidance of Pneumocystis jirovecii pneumonia in renal transplant recipients","volume":"40","author":"Zhang","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2022.109636_b0070","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkw158","article-title":"Peter Schellongowski.ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients","volume":"71","author":"Maschmeyer","year":"2016","journal-title":"J. Antimicrob. Chemother."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:05:31Z","timestamp":1736431531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922011213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":14,"alternative-id":["S1567576922011213"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109636","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumocystis jiroveci Pneumonia secondary to tyrosine kinase inhibitor with blinatumomab therapy: A case report","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109636"}}